August NCI Office of Advocacy Relations Update

National Cancer Institute sent this bulletin at 08/03/2020 03:26 PM EDT
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

 

 

You are subscribed to the Office of Advocacy Relations Update from the National Cancer Institute. Read highlights of the latest news and upcoming events happening at NCI. 

 

Upcoming Events

National Cancer Advisory Board (NCAB) Virtual Meeting, September 1-3, 2020

Note: Videocasts for advisory board meetings will be available at https://videocast.nih.gov/ the day of the meeting and will be archived shortly after for viewing on demand.

Upcoming NCI Director Appearances

  

Dr. Sharpless will be speaking at the following in August:

 

ASCO20 Education Program (Virtual), August 8, 2020

For ongoing updates, follow @NCIDirector on Twitter.

Recent NCI Announcements

  

Dr. Emily S. Tonorezos Named Director of NCI Office of Cancer Survivorship (August 3, 2020)

Recent Cancer Currents Posts

  

How CRISPR is Changing Cancer Research and Treatment (July 27, 2020)

The gene-editing tool CRISPR is changing the way scientists study cancer, and may change how cancer is treated. This in-depth blog post describes how this revolutionary technology is being used to better understand cancer and create new treatments.

 

Rediscovered Drugs Hit Leukemia from Two Different Angles (July 21, 2020)

Two rediscovered drugs, bisantrene and brequinar, slowed the growth of acute myeloid leukemia in studies of mice. The drugs blocked the activity of a protein called FTO, killing cancer stem cells and helping the immune system attack the cancer.

 

Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes (July 16, 2020)

Three recently launched NCI-supported studies could help researchers better understand the causes of racial/ethnic disparities in ovarian cancer. The ultimate goal is to eliminate disparities and improve survival for all women with the disease.

 

CCDI Activities Enhance NCI’s Childhood and AYA Cancer Research (July 13, 2020)

Since launching the Childhood Cancer Data Initiative, NCI has undertaken a range of research activities to support this important effort. In this Cancer Currents post, NCI Director Dr. Norman Sharpless provides an update on these efforts.

 

A New FDA Approval Furthers the Role of Genomics in Cancer Care (July 8, 2020)

FDA’s approval of pembrolizumab (Keytruda) to treat people whose cancer is tumor mutational burden-high highlights the importance of genomic testing to guide treatment, including for children with cancer, according to NCI Director Dr. Ned Sharpless.

 

Read more news at the Cancer Currents blog.